ALT vs LLY: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALT and LLY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALT and LLY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Altimmune is a clinical-stage biopharmaceutical company focused on metabolic and liver disease. Its lead candidate, pemvidutide, is a dual agonist of the GLP-1 and glucagon receptors designed to drive weight loss while preserving lean mass and improving liver health. The company has run a Phase 2 obesity program (MOMENTUM) and a Phase 2b MASH program (IMPACT), and reported positive 48-week topline MASH results in December 2025 showing significant improvements in liver fat, weight, and fibrosis markers versus placebo.

Full ALT guide

Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Its tirzepatide molecule is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and these products have driven explosive revenue growth amid surging demand for metabolic treatments. Beyond GLP-1s, Lilly has a deep and diversified pipeline and franchises across diabetes, oncology, immunology, and neuroscience, including a closely watched effort in Alzheimer's disease (donanemab, marketed as Kisunla). The company invests heavily in research and in expanding manufacturing capacity to meet incretin demand. Eli Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana. It has become one of the most valuable healthcare companies in the world, with the obesity and diabetes opportunity central to its growth story, balanced by a premium valuation and the eventual prospect of competition and patent expirations.

Full LLY guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ALT drivers: Differentiated GLP-1/glucagon profile; MASH opportunity.
• LLY drivers: GLP-1 obesity and diabetes leadership; Manufacturing scale-up.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Altimmune is a single-asset, clinical-stage company with no approved products and no revenue, so a failed or disappointing Phase 3 readout could sharply reduce the stock. For LLY, lLY trades at a premium valuation, so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply.

Pick ALT if you believe its drivers more; LLY if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALT and LLY guides.

ALT. As a pre-revenue biotech, Altimmune cannot be valued on earnings or P/E; its market value reflects the probability-weighted commercial potential of pemvidutide. The roughly $535 million cash position is a key strength because it funds expensive Phase 3 work, but the eventual value depends on trial outcomes and approval, both of which are uncertain.

LLY. Eli Lilly trades at a premium pharma multiple that prices in continued rapid growth from the obesity and diabetes franchise plus pipeline optionality. The valuation debate centers on how large, durable, and profitable the incretin market proves to be and how competition (chiefly Novo Nordisk and emerging oral incretins) shapes pricing and share. Figures are approximate and should be verified against the latest filings before drawing conclusions.

Headline figures (approximate, Q1 2026): ALT shows product revenue None (clinical-stage), cash + short-term investments ~$535 million, lead program Pemvidutide (obesity, MASH), mash stage Phase 3 (PERFORMA) planned H2 2026; LLY shows revenue (ttm) ~$45 to 55 billion and growing fast (verify), operating margin ~30%+ (verify), gross margin ~80% (typical for branded pharma), p/e (ttm) ~40x to 60x (premium; verify).

ALT and LLY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALT and LLY exposure against your real portfolio. It is not an investment adviser.